Sherri-Ann Burnett-Bowie, MD, MPH

2010 DICP Faculty Fellowship Alumni

SHERRI-ANN BURNETT-BOWIE, MD, MPH, Assistant Professor of Medicine, Harvard Medical School; Clinical Investigator, Massachusetts General Hospital Department of Medicine/Endocrine Unit

Mentor: Dr. Joel Finkelstein, M.D., Associate Professor of Medicine, Harvard Medical School, Massachusetts General Hospital

Department Chair: Henry M. Kronenberg, M.D., Head of the Department of Medicine, Massachusetts General Hospital; Professor of Medicine, Harvard Medical School

Project Title:  "Dietary and Hormonal Regulation of FGF23"

Project Description:

This proposal investigates fibroblast growth factor 23 (FGF23) regulation by different vitamin D formulations (Specific Aim 1) and FGF23 diurnal variation (Specific Aim 2).  FGF23 is a novel phosphate (PO4)-and vitamin D-regulating hormone.  Excess FGF23 causes hypophosphatemia, osteomalacia/rickets, and fractures.  FGF23 excess also occurs in renal failure and appears to predict mortality in hemodialysis patients.  Thus, abnormal FGF23 regulation appears central to both rare and common diseases.  Furthermore, FGF23 physiology is important in both endocrinology and nephrology; thus this project has a multidisciplinary focus.  In Specific Aim 1, 52 African-American and Caucasian men and women, aged 18-45, with 25-hydroxyvitamin D levels (25OHD)  < 24 ng/mL (by mass spectroscopy) will be randomized to ergocalciferol 50,000 international units weekly or calcitriol 0.5 mcg daily for 12 weeks.  This project will determine if there are racial differences in the stimulation of FGF23 by vitamin D and also if there are differences in the stimulation of FGF23 based on the use of dietary versus activated vitamin D.  In Specific Aim 2, 32 African-American and Caucasian subjects with 25OHD > 24 ng/mL will consume a standardized diet for three days and then undergo frequent blood and urine sampling over 24-hours to determine if FGF23 levels vary diurnally.  Recruitment for Specific Aim 1 is ongoing and recruitment for Specific Aim 2 will start in the next month.  Recruitment for both will be completed in ~ 1 year.   Data analysis and manuscript preparation will be completed in an additional 6 months.


Sherri-Ann M. Burnett-Bowie, MD, MPH is an endocrinologist and clinical researcher in the Bone and Mineral Metabolism Unit at Massachusetts General Hospital and an instructor of medicine at Harvard Medical School.  She received her B.A. in Biochemical Sciences from Harvard College in 1993, her M.D. from the University of Pittsburgh in 1997, and M.P.H. degree from the Harvard School of Public Health in 2005. She completed residency in Internal Medicine and fellowship in Endocrinology at Massachusetts General Hospital.  Her research is focused on defining the physiology of a new phosphate-regulating hormone (FGF23); the relationship between vitamin D deficiency and insulin resistance; and clinical trials of treatments for osteoporosis.  She sees patients with bone and mineral disorders, as well as general endocrine disorders.